1. Home
  2. SPT vs RCKT Comparison

SPT vs RCKT Comparison

Compare SPT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$5.73

Market Cap

327.6M

Sector

Technology

ML Signal

HOLD

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

HOLD

Current Price

$4.65

Market Cap

534.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
RCKT
Founded
2010
1999
Country
United States
United States
Employees
N/A
202
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.6M
534.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SPT
RCKT
Price
$5.73
$4.65
Analyst Decision
Buy
Buy
Analyst Count
8
14
Target Price
$12.38
$29.65
AVG Volume (30 Days)
1.7M
3.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
N/A
EPS
N/A
N/A
Revenue
$457,547,000.00
N/A
Revenue This Year
$9.03
N/A
Revenue Next Year
$8.83
$51.17
P/E Ratio
N/A
N/A
Revenue Growth
12.72
N/A
52 Week Low
$5.39
$2.19
52 Week High
$24.74
$8.26

Technical Indicators

Market Signals
Indicator
SPT
RCKT
Relative Strength Index (RSI) 37.54 54.89
Support Level N/A $2.99
Resistance Level $7.39 $5.39
Average True Range (ATR) 0.32 0.34
MACD 0.06 -0.07
Stochastic Oscillator 36.81 40.74

Price Performance

Historical Comparison
SPT
RCKT

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: